论文部分内容阅读
目的探讨依达拉奉联合阿魏酸钠治疗急性脑梗死的临床疗效。方法 60例急性脑梗死患者随机分为对照组(30例)和治疗组(依达拉奉联合阿魏酸钠30例)。对照组采用基础治疗加复方丹参注射液;治疗组在基础治疗上加用依达拉奉和阿魏酸钠,疗程14d,于治疗前及治疗后用神经缺损情况评分[美国国立卫生院卒中量表(NIHSS)]、中风患者运动功能评分[简化FMA(SFMA)评分]及日常生活活动功能能力评分(ADL)进行疗效评价。结果治疗组治疗后NIH-SS、SFMA、ADL评分均较对照组有改善(P<0.05或P<0.01)。结论依达拉奉联合阿魏酸钠治疗急性脑梗死疗效肯定。
Objective To investigate the clinical efficacy of edaravone combined with sodium ferulate in the treatment of acute cerebral infarction. Methods Sixty patients with acute cerebral infarction were randomly divided into control group (30 cases) and treatment group (edaravone combined with sodium ferulate 30 cases). The control group was treated with Fufang Danshen injection. The treatment group was treated with edaravone and sodium ferulate for 14 days. The scores of neurological deficits before and after treatment were compared with those of the control group [National Institutes of Health Stroke Volume (NIHSS), motor function score of stroke patients (SFMA score), and ADL score. Results The scores of NIH-SS, SFMA and ADL in the treatment group were improved compared with the control group (P <0.05 or P <0.01). Conclusion Edaravone combined with sodium ferulate in the treatment of acute cerebral infarction is sure.